Quantcast
Last updated on April 17, 2014 at 15:32 EDT

Latest Ventricular assist device Stories

2013-02-18 23:03:12

During a recent webinar hosted by AllMed Healthcare Management, Dr. Dale Mueller, a board-certified thoracic and cardiac surgeon, discussed the use of left ventricular assist devices (LVADs) for mechanical circulatory support and their potential complications. Portland, OR (PRWEB) February 18, 2013 During a recent webinar hosted by AllMed Healthcare Management, Dr. Dale Mueller, a board-certified thoracic and cardiac surgeon, discussed the use of left ventricular assist devices (LVADs) for...

2013-02-11 08:26:40

PLEASANTON, Calif., Feb. 11, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Leerink Swann 2013 Global Healthcare Conference on Thursday, February 14. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 9:00 a.m., Eastern Standard Time (6:00 a.m., Pacific Standard...

2013-02-08 08:25:20

FRAMINGHAM, Mass. and SYDNEY, Feb. 8, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Leerink Swann Global Healthcare Conference at 8:30 a.m. Eastern Standard Time on Wednesday, February 13, 2013. The conference is being held February 13-14 at...

2013-02-05 16:23:32

PLEASANTON, Calif., Feb. 5, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the fourth quarter of 2012. "Thoratec had an impressive year in 2012, with sales growth of 16 percent driven by our HeartMate II® and CentriMag® product lines, highlighting our leadership positions in chronic and acute mechanical circulatory...

2013-01-28 08:29:43

PLEASANTON, Calif., Jan. 28, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for fiscal year 2012 on Tuesday, February 5. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Standard Time (4:30 p.m., Eastern...

2013-01-07 16:25:11

FRAMINGHAM, Mass. and SYDNEY, Jan. 7, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it expects total revenues for the fourth quarter of 2012 will be approximately $32 million, bringing expected full-year 2012 revenues to approximately $110 million. "These results reflect positive initial...

2013-01-07 08:30:31

PLEASANTON, Calif., Jan. 7, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to commence the REVIVE-IT study utilizing the HeartMate II® Left Ventricular Assist System. REVIVE-IT (Randomized Evaluation of VAD InterVEntion before Inotropic...

2013-01-03 08:26:57

FRAMINGHAM, Mass. and SYDNEY, Australia, Jan. 3, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 31(st) Annual J.P. Morgan Healthcare Conference at 10:30 a.m. Pacific Standard Time (1:30 p.m. EST) on Monday, January 7. The conference is being...

2013-01-03 08:26:12

PLEASANTON, Calif., Jan. 3, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 31(st) Annual J.P. Morgan Healthcare Conference on Monday, January 7. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 8:00 a.m., Pacific Standard Time (11:00 a.m., Eastern Standard...

2012-12-18 12:27:51

Dasse named President; Gellman named Senior Vice President, Engineering WALTHAM, Mass., Dec. 18, 2012 /PRNewswire/ -- GeNO LLC, a privately held pharmaceutical company that is developing innovative nitric oxide (NO) generation and delivery platforms, today announced that Kurt Dasse, a member of the company's Board of Managers and formerly Executive Vice President, has been appointed President of GeNO. Prior to joining GeNO, he served as President and CEO of Waltham, Massachusetts based...


Latest Ventricular assist device Reference Libraries

0_886104d1c1c698f3a531e056704457d5
2010-10-14 16:46:25

The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...

More Articles (1 articles) »